This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
her2
HER2
ErbB2/HER2 receptor tyrosine kinase; ligandless but preferred ErbB dimerization partner amplifying EGFR/HER3/HER4 signaling. Amplified in 15–20% of breast cancer and 15% of gastric cancer. Targeted by trastuzumab, pertuzumab, T-DM1, and T-DXd (trastuzumab deruxtecan).
Entry Metadata
| Field | Value |
|---|---|
| ID | her2 |
| Name | HER2 |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. · PubMed 3798106
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792. · PubMed 11248153
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2022;387(1):9-20. · PubMed 35665782